LQDA Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$54.38median target· current $34.35 (+58.3%)8 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio24.71Forward 10.53
EPS (TTM)$1.390.0% YoY
Profit margin30.7%HEALTHCARE
Market cap$3.07BMid cap
Valuation
- Forward P/E
- 10.53
- PEG ratio
- —
- P/B
- 30.96
- P/S (TTM)
- 6.82
- EV/EBITDA
- 33.40
Profitability & growth
- ROE (TTM)
- 131.8%
- Operating margin
- 49.8%
- Revenue growth YoY
- 1843.0%
- Dividend yield
- —
- Beta
- 0.61
Last earnings
Aug 12, 2026 · Estimate $0.70 · Reported $-0.49
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Liquidia Technologies Inc
Company profileLiquidia Corporation, a biopharmaceutical company, develops, manufactures, and markets various products for the unmet needs of patients in the United States. The company is headquartered in Morrisville, North Carolina.
Classification
- Sector
- Healthcare
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 419 DAVIS DRIVE, MORRISVILLE, NC
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$3.07B
Shares outstanding$89.5M
52W high$93.61
52W low$21.94
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent